- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
I Mab (NBP)
Track the I Mab share price today and view real-time NBP share price data, including charts, technicals, and key financials. View the NBP premarket stock price ahead of the market session or assess the after hours quote. Explore NBP stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the I Mab Stock Price Today?
The I Mab stock price today is 1.840.
What Is the Stock Symbol for I Mab?
The stock symbol for I Mab is ""NBP.""
What Stock Exchange Does I Mab Trade On?
I Mab is listed and trades on the NASDAQ stock exchange.
Is I Mab a Good Stock to Buy?
Determining whether I Mab or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NBP quote. (ISIN: US44975P1030)
What Is the I Mab Stock Price Today?
The I Mab stock price today is 1.840.
What Is the Stock Symbol for I Mab?
The stock symbol for I Mab is ""NBP.""
What Stock Exchange Does I Mab Trade On?
I Mab is listed and trades on the NASDAQ stock exchange.
Is I Mab a Good Stock to Buy?
Determining whether I Mab or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NBP quote. (ISIN: US44975P1030)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.790
1.900
52 wk Range
1.460
6.790
NBP is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.7901.900
52 wk Range
1.4606.790
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NBP Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
8.250
Upside
+348.37%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Form 4 I Mab For: 8 July- Investing.com
Form 4 I Mab For: 7 July- Investing.com
I Mab receives Investment Bank Analyst Rating Update- Investing.com
Pro
Form 4 I Mab For: 10 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 8.250
(+348.37% Upside)
I Mab Earnings Call Summary for Q2/2026
- NovaBridge ended Q2 2026 with $216M in cash and no debt, sufficient to fund givastomig through 2028 Phase III interim readout.
- Shares fell 8.59% to $1.81 despite positive pipeline updates; no revenue reported and analysts expected 12-cent loss per share.
- Givastomig received FDA Fast Track status in June, showing 75% response rate and 16.9-month median PFS in Phase I-B trial data.
- Company plans Phase III initiation for givastomig in Q4 2026 and Phase IIb study for VIS-101 ophthalmology asset in H2 2026.
- Management highlighted givastomig's simple infusion profile as competitive advantage in crowded Claudin 18.2 cancer treatment space.
Last Updated: 21/08/2026, 12:12 am
Read Full TranscriptEarnings
Latest Release
20/08/2026
EPS / Forecast
-0.16 / -0.12
Revenue / Forecast
-- / --
Compare NBP to Peers and Sector
Metrics to compare | NBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNBPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −7.7x | −0.4x | |
PEG Ratio | 0.02 | −0.17 | 0.00 | |
Price/Book | 1.1x | 3.8x | 2.6x | |
Price / LTM Sales | - | 21.8x | 3.1x | |
Upside (Analyst Target) | 362.0% | 160.9% | 47.7% | |
Fair Value Upside | Unlock | −0.7% | 6.5% | Unlock |
NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the I Mab (NBP) Stock Price Today?
The I Mab stock price today is 1.840 USD.
What Stock Exchange Does I Mab Trade On?
I Mab is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for I Mab?
The stock symbol for I Mab is "NBP."
What Is the I Mab Market Cap?
As of today, I Mab market cap is 213.440M USD.
What Is I Mab's Earnings Per Share (TTM)?
The I Mab EPS (TTM) is -1.042.
When Is the Next I Mab Earnings Date?
I Mab will release its next earnings report on 12/11/2026.
From a Technical Analysis Perspective, Is NBP a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has I Mab Stock Split?
I Mab has split 0 times.
What is the current trading status of I Mab (NBP)?
As of 31/08/2026, I Mab (NBP) is trading at a price of 1.840 USD, with a previous close of 1.840 USD. The stock has fluctuated within a day range of 1.790 USD to 1.900 USD, while its 52-week range spans from 1.460 USD to 6.790 USD.
What Is I Mab (NBP) Price Target According to Analysts?
The average 12-month price target for I Mab is 8.250 USD, with a high estimate of 9 USD and a low estimate of 7 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +348.37% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.